TY - JOUR
T1 - Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome
AU - Garcia-Cordero, Indira
AU - Vargas-Gonzalez, Juan Camilo
AU - Hadian, Mohsen
AU - Bayram, Ece
AU - Rodriguez-Porcel, Federico
AU - Couto, Blas
AU - Iyer, Jay
AU - Golbe, Lawrence I.
AU - Stephen, Christopher D.
AU - Pantelyat, Alexander
AU - Dale, Marian L.
AU - McFarland, Nikolaus
AU - Xie, Tao
AU - Swan, Matthew
AU - Kang, Kyurim
AU - Gunzler, Douglas
AU - Wills, Anne Marie
AU - Boxer, Adam
AU - Litvan, Irene
AU - Lang, Anthony
AU - Tartaglia, Maria Carmela
N1 - Publisher Copyright:
© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2025/7
Y1 - 2025/7
N2 - INTRODUCTION: Cognitive impairment is common but often overlooked due to motor symptoms in progressive supranuclear palsy-Richardson syndrome (PSP-RS). This study investigates whether cognitive deficits predict disease progression in PSP-RS. METHODS: A total of 146 PSP-RS from the Tilavonemab trial were evaluated at baseline and over 52 weeks using the PSP-Rating Scale (PSPRS), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and the Unified Parkinson's Disease Rating Scale Part-II (UPDRS-II). Multiple linear regression analyses were performed between the RBANS, UPDRS-II, and the PSPRS change. Clinical scores, gray matter volumes, and neurofilament-light chain (NfL) were compared using analyses of covariance (ANCOVAs) and linear mixed models between language score-groups. RESULTS: Lower RBANS-language at baseline predicted greater PSPRS worsening over time. The low language-score group showed poorer cognitive performance, elevated NfL, and reduced gray matter volume in language-related areas. DISCUSSION: Speech/language deficits predict worse prognosis in PSP-RS, emphasizing the value of including language scores in clinical trials. Highlights: Speech and language deficits predict a worse prognosis in progressive supranuclear palsy-Richardson syndrome (PSP-RS). Lower language scores are associated with worse cognitive performance over time. Lower language scores related to higher neurofilament-light chain (NfL) at baseline. The low language-score group presented greater atrophy in language-related brain areas. Stratifying PSP-RS cases using language scores may improve clinical trials.
AB - INTRODUCTION: Cognitive impairment is common but often overlooked due to motor symptoms in progressive supranuclear palsy-Richardson syndrome (PSP-RS). This study investigates whether cognitive deficits predict disease progression in PSP-RS. METHODS: A total of 146 PSP-RS from the Tilavonemab trial were evaluated at baseline and over 52 weeks using the PSP-Rating Scale (PSPRS), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and the Unified Parkinson's Disease Rating Scale Part-II (UPDRS-II). Multiple linear regression analyses were performed between the RBANS, UPDRS-II, and the PSPRS change. Clinical scores, gray matter volumes, and neurofilament-light chain (NfL) were compared using analyses of covariance (ANCOVAs) and linear mixed models between language score-groups. RESULTS: Lower RBANS-language at baseline predicted greater PSPRS worsening over time. The low language-score group showed poorer cognitive performance, elevated NfL, and reduced gray matter volume in language-related areas. DISCUSSION: Speech/language deficits predict worse prognosis in PSP-RS, emphasizing the value of including language scores in clinical trials. Highlights: Speech and language deficits predict a worse prognosis in progressive supranuclear palsy-Richardson syndrome (PSP-RS). Lower language scores are associated with worse cognitive performance over time. Lower language scores related to higher neurofilament-light chain (NfL) at baseline. The low language-score group presented greater atrophy in language-related brain areas. Stratifying PSP-RS cases using language scores may improve clinical trials.
KW - PSP-Rating Scale
KW - PSP-Richardson syndrome
KW - RBANS
KW - cognition
KW - disease progression
KW - gray matter volume
KW - language
KW - neurofilament-light chain
UR - https://www.scopus.com/pages/publications/105011349103
U2 - 10.1002/alz.70485
DO - 10.1002/alz.70485
M3 - Article
C2 - 40684253
AN - SCOPUS:105011349103
SN - 1552-5260
VL - 21
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 7
M1 - e70485
ER -